Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
| 21.94 | |
| 21.48 | |
| - | |
| 22.2 | |
| 21.23 | |
| 4.22-24.3773 | |
| 1 355 M | |
| 64 412 K | |
| 62 303 K | |
| -0.71 | |
| 2.224 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Nurix Therapeutics, Inc. Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in CLL and other non-Ho...
Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 14.7% higher at $68.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in t...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
